Sarepta Therapeutics’ (SRPT) “Overweight” Rating Reaffirmed at Piper Sandler

Piper Sandler reissued their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report released on Monday, Benzinga reports. Piper Sandler currently has a $205.00 price target on the biotechnology company’s stock.

Other research analysts also recently issued research reports about the company. Bank of America increased their target price on Sarepta Therapeutics from $166.00 to $213.00 and gave the company a buy rating in a report on Friday, June 21st. BMO Capital Markets increased their target price on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an outperform rating in a report on Monday, June 24th. Evercore ISI increased their target price on Sarepta Therapeutics from $139.00 to $185.00 and gave the company an in-line rating in a report on Monday, June 24th. TheStreet raised Sarepta Therapeutics from a d rating to a c- rating in a report on Monday, March 4th. Finally, Cantor Fitzgerald reissued a neutral rating and issued a $128.00 target price on shares of Sarepta Therapeutics in a report on Friday, June 21st. Five equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus target price of $187.72.

Sarepta Therapeutics Trading Down 0.7 %

Sarepta Therapeutics stock opened at $153.11 on Monday. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44. Sarepta Therapeutics has a one year low of $55.25 and a one year high of $173.25. The stock has a market capitalization of $14.47 billion, a PE ratio of 1,391.91 and a beta of 0.89. The business’s fifty day moving average is $131.86 and its 200 day moving average is $123.74.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, beating the consensus estimate of ($0.11) by $0.84. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The company had revenue of $413.50 million for the quarter, compared to analysts’ expectations of $375.52 million. During the same period last year, the firm posted ($1.44) earnings per share. Sarepta Therapeutics’s revenue was up 63.1% compared to the same quarter last year. On average, sell-side analysts predict that Sarepta Therapeutics will post 3.71 EPS for the current year.

Insider Buying and Selling

In related news, insider Bilal Arif sold 7,859 shares of the stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the completion of the sale, the insider now owns 21,261 shares in the company, valued at $3,467,243.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Sarepta Therapeutics news, insider Dallan Murray sold 3,635 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total transaction of $508,900.00. Following the completion of the transaction, the insider now owns 18,125 shares in the company, valued at approximately $2,537,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Bilal Arif sold 7,859 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $163.08, for a total value of $1,281,645.72. Following the transaction, the insider now owns 21,261 shares of the company’s stock, valued at approximately $3,467,243.88. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,451 shares of company stock worth $8,086,386. 7.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Several institutional investors have recently added to or reduced their stakes in SRPT. Envestnet Asset Management Inc. grew its holdings in Sarepta Therapeutics by 152.3% during the 3rd quarter. Envestnet Asset Management Inc. now owns 35,642 shares of the biotechnology company’s stock valued at $4,321,000 after buying an additional 21,514 shares in the last quarter. Hsbc Holdings PLC boosted its holdings in shares of Sarepta Therapeutics by 26.0% in the 3rd quarter. Hsbc Holdings PLC now owns 2,515 shares of the biotechnology company’s stock worth $305,000 after purchasing an additional 519 shares during the period. Natixis Advisors L.P. boosted its holdings in shares of Sarepta Therapeutics by 0.6% in the 3rd quarter. Natixis Advisors L.P. now owns 26,026 shares of the biotechnology company’s stock worth $3,155,000 after purchasing an additional 160 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Sarepta Therapeutics by 79.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 5,239 shares of the biotechnology company’s stock worth $635,000 after purchasing an additional 2,326 shares during the period. Finally, Advisors Asset Management Inc. boosted its holdings in shares of Sarepta Therapeutics by 6.2% in the 3rd quarter. Advisors Asset Management Inc. now owns 22,704 shares of the biotechnology company’s stock worth $2,752,000 after purchasing an additional 1,335 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.